These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20213666)

  • 1. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation.
    Moreno A; Pérez-Elías MJ; Casado JL; Fortún J; Bárcena R; Quereda C; Del Campo S; Gutiérrez C; Pastor O; Nuño J; Fernandez A; Moreno S
    Liver Transpl; 2010 Apr; 16(4):530-2. PubMed ID: 20213666
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review.
    Miro JM; Ricart MJ; Trullas JC; Cofan F; Cervera C; Brunet M; Tuset M; Manzardo C; Oppenheimer F; Moreno A
    Transplant Proc; 2010 Nov; 42(9):3887-91. PubMed ID: 21094878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy.
    Soriano-Sarabia N; Abad MA; Vallejo A; Gutiérrez S; Leal M
    Clin Microbiol Infect; 2006 Mar; 12(3):290-3. PubMed ID: 16451419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation.
    Ciuffreda D; Pantaleo G; Pascual M
    Transpl Int; 2007 Aug; 20(8):649-58. PubMed ID: 17425723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy.
    Fraaij PL; Verweel G; van Rossum AM; van Lochem EG; Schutten M; Weemaes CM; Hartwig NG; Burger DM; de Groot R
    Clin Infect Dis; 2005 Feb; 40(4):604-8. PubMed ID: 15712085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children.
    Resino S; Resino R; Maria Bellón J; Micheloud D; Gutiérrez MD; de José MI; Ramos JT; Fontelos PM; Ciria L; Muñoz-Fernández MA;
    Clin Infect Dis; 2006 Jul; 43(2):243-52. PubMed ID: 16779753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
    Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: is a 400 mg once-daily dose enough?
    Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
    J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
    [No Abstract]   [Full Text] [Related]  

  • 9. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients.
    Marfo K; Greenstein S
    Transplant Proc; 2009 Nov; 41(9):3796-9. PubMed ID: 19917390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy.
    Posavad CM; Wald A; Kuntz S; Huang ML; Selke S; Krantz E; Corey L
    J Infect Dis; 2004 Aug; 190(4):693-6. PubMed ID: 15272395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract.
    Pasquier CJ; Moinard N; Sauné K; Souyris C; Lavit M; Daudin M; Izopet J; Bujan L
    AIDS; 2008 Sep; 22(14):1894-6. PubMed ID: 18753873
    [No Abstract]   [Full Text] [Related]  

  • 14. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
    Papendorp SG; van den Berk GE
    AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laser scanning confocal ophthalmoscopy and polarimetry of human immunodeficiency virus patients without retinopathy, under antiretroviral therapy.
    Besada E; Shechtman D; Black G; Hardigan PC
    Optom Vis Sci; 2007 Mar; 84(3):189-96. PubMed ID: 17435532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
    Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
    HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions.
    Soriano V; Rivas P; Nuñez M
    Clin Infect Dis; 2008 Dec; 47(11):1486-9. PubMed ID: 18937578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.